Rapid IO Signature Development
IO 360™ Panel
Faster than qPCR. Simpler than NGS.
Expertly Curated. Ready to Use.
New Cell Press Supplement
Pathological Mechanisms of Neurodegeneration
Small Sample. Big Insight.
nCounter® Analysis System
More insights from
Prosigna® Breast Cancer Prognostic Gene Signature Assay
Empowering personalized treatment decisions
Learn More *See product pages for regulatory status information
on actionable answers
Sergio Rutella, M.D., Ph.D., FRCPath is a Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre at Nottingham Trent University. His research focuses on acute myeloid leukemia (AML), an aggressive form of cancer that originates in the bone marrow. We recently spoke with Dr. Rutella about his research and the challenges of studying this disease.
Robin Lynn White
December 14, 2017
nCounter® Analysis in Complex Biology:
Gene expression profile predicts response to pembrolizumab
A video review of JCI publication by Ayers, et al:
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Simultaneous Profiling of Proteins and RNA with 3D Flow ™ Analysis - APR 05, 2018 10:30 AM PST
Miguel A. Tam, Ph.D. Senior Manager, Product Realization and Marketing, BioLegend and Kit Fuhrman, Ph.D. Senior Field Application Scientist, NanoString
Deeper analysis of immunological processes require increasingly sophisticated approaches. To help address this need, we developed 3D Flow™ Analysis, a streamlined workflow that integrates standard cell sorting with NanoString nCounter® analysis. This workflow enables the highly multiplexed digital detection of 770 RNA and 30 proteins from a single sample.
Challenges with gene expression profiling in a biotech setting and recent technical advances with NanoString PlexSet™ - Originally aired JAN 24, 2018
Matt Goddeeris, Principal Scientist, Mitobridge
Mitobridge has used NanoString PlexSet Reagents for gene expression, systematically interrogating disease-related changes in mitochondrial activity and translating unique insights into potential new treatments.